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Abstract
I In nt tr ro od du uc ct ti io on n: : Despite the development and wide implementation of Directly
Observed Therapy Strategies (DOTS), multidrug-resistant tuberculosis (MDR-TB)
remains a serious global health threat. In this study, the role of host immune
response in patients with MDR-TB is investigated and compared with that of
patients with smear-positive drug-sensitive tuberculosis (SP-TB).
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s: :   27 patients with SP-TB, 20 patients with MDR-TB, and 
20  healthy  controls  were  included  in  the  study.  Immune  parameters  were
determined by flow cytometry using monoclonal antibodies in order to compare
the percentage values of these markers in the two study groups and the control
group.
R Re es su ul lt ts s: :   The levels of lymphocyte subgroups in the gate of CD45(+)/CD14(–)
lymphocyte: CD45(+), CD3(+), CD4(+), NK, CD3/HLA-DR, CD 95(+) cells were
significantly lower; by contrast CD23(+), CD25(+), CD19(+), CD4(+)/CD8(+), HLA-DR
cells were found to be lower, but not significantly so in patients with MDR-TB,
compared to levels in patients in the SP-TB and control groups. Besides these
findings, the levels of NKT cells and ʳʴ TCR(+) cells were significantly higher in the
MDR-TB than in the healthy control and SP-TB group.
C Co on nc cl lu us si io on ns s: : The lower levels of CD3/HLA-DR, CD4 (+), Fas (+), and NK, and the
higher level of NKT together with ʳʴ T cells in patients with MDR-TB compared to
those in SP-TB may indicate a profound immune suppression in MDR-TB patients
and thereby may denote an accumulation in the bacterial load. Our findings may
shed light on the pathogenesis and prognosis of MDR tuberculosis, and may point
towards the use of flow cytometry findings as an aid to early diagnosis in MDR-TB
patients.
K Ke ey y   w wo or rd ds s: :   HLA-DR, ʳʴ T cell, NK-T cell, multidrug-resistant tuberculosis.
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Introduction
Despite the development of the directly observed
therapy  strategy  (DOTS)  multidrug-resistant
tuberculosis (MDR-TB) is still an important problem
that threatens global community health [1-3]. Nearly 
50  billion  people  are  infected  with  MDR-TB
worldwide and the number is increasing every year
as new cases are infected with MDR-TB strains [4].
Most of the risk factors for the emergence of
drug resistance in tuberculosis are acquired. For
example, inadequate treatment due to adverse drug
reactions, economic hardships, and non-adherence
to  drug  therapy  when  symptoms  resolve  may 
be responsible for the current high prevalence of 
MDR-TB. 
In addition, there is a lack of clarity regarding the
genetic control of tuberculosis which, if resolved,
could  help  to  explain  why  active  tuberculosis
disease only emerges in a relatively small number
of infected people [5].
Protection against Mycobacterium tuberculosis
(M. tbc) is based on cell-mediated immunity, most
importantly involving CD4 (+) and CD8 (+) T-cell
subsets  [6].  The  CD4 T  cell  is  believed  to  be
responsible for regulating the immune response
to M. tbc. When activated, CD4 cells proliferate and
produce  cytokines  which  in  turn  activate
mononuclear phagocytes to control the growth of
intracellular mycobacteria [7].
The primary function of the CD8 (+) lymphocytes
(T suppressor/cytotoxic) is the lysis and apoptosis
of the infected cells. In some studies, it was found
that in active tuberculosis patients, CD4 and CD8
counts are decreased, but the CD4/CD8 ratio is
increased compared to the healthy population [8].
Findings in peripheral blood contrast with other
research suggesting an increase in CD4 cells and 
a reduction in CD8 cells in bronchoalveolar lavage
fluid  leading  to  an  increased  CD4/CD8  ratio,
particularly where there is moderate or advanced
pulmonary involvement. The researchers attributed
these  findings  to  compartmentalization  or
sequestration of CD4+ lymphocytes in cases of high
grade pulmonary TB [9].
The human leukocyte antigen (HLA) system is
a powerful genetic marker. Host immune response
and infectious diseases are genetically controlled
by the HLA system [10].
In M. tbc infection, HLA factors are associated
with the type and severity of the disease. Although
immune suppression and the progress of disease
are controlled by the HLA system, innate resistance
to Mycobacterium infection appears to be dependent
on  non-HLA  genes  [11,  12].  However,  genetic
susceptibility of the host to multidrug-resistant
tuberculosis (MDR-TB) is not fully understood [13].
In this study, we aimed to compare the levels of
CD3+/HLA-DR, HLA-DR and lymphocyte subgroups
(CD45, CD3, CD4, CD19, CD 23, ʳʴ-T cell, NK-T) and
the marker of apoptosis Fas (CD95) in smear-
positive drug-sensitive tuberculosis (SP-TB) with
these values in smear-positive MDR-TB cases.
Where the immune profiles of the two groups
were different, the effect of immune status in the
development and clinical progress of MDR-TB was
examined. 
Material and methods
P Pa at ti ie en nt ts s   a an nd d   s st tu ud dy y   d de es si ig gn n
20 healthy controls, 27 patients with sputum
smear-positive pulmonary tuberculosis sensitive to
primary anti-TB therapy, and 20 patients with
sputum smear-positive MDR-TB were included in
the study.
All of the cases were HIV (–). In the MDR-TB
group, two of the cases had not been previously
treated with anti-tuberculosis agents (primary
MDR), while 18 of the cases had been treated at
least two times before the study (secondary
MDR).
Where  possible,  patients  without  any  co-
morbidities were selected. In all cases, baseline data
such as history (both medical and family histories,
including TB family history), physical examination,
biochemical parameters and complete blood count
(particularly haemoglobin [Hb], haematocrit [Htc]
and leukocyte values) were recorded.
Mycobacterium tuberculosis was isolated from
the sputum and cultured according to the standard
techniques, and sensitivity testing was performed
using the absolute concentration method [14, 15].
I Im mm mu un ne e   p pr ro of fi il le e   d de et te er rm mi in na at ti io on n
The patients’ immune profiles were determined
by analyzing blood samples, by whole blood lysis on
flow cytometry (Becton-Dickinson FACSCalibur, San
Jose, CA) following heparinization and treatment
with  fluorochrome-conjugated  monoclonal
antibodies (anti-human IgG1-FITC/IgG2a PE isotype
control, anti-human CD45-FITC, CD3-FITC, CD4-FITC,
CD8-PE,  CD19-PE,  CD16/56-PE(NK),  HLA-DR, 
CD23-PE, CD25-FITC, Fas(CD95)-PE and ʳʴ-T cell-PE).
In order to detect the changes in percentage values
of these markers, first 100 ﾵl of heparinized blood
was placed into all test tubes, and then 10 ﾵl of
isotype control was added into one tube and 10 ﾵl
of monoclonal antibody into the others. After
incubating for 30 min at room temperature in
a dark room, erythrocytes were removed using
500 ﾵl of erythrocyte lysis buffer and 5 ml of
phosphate buffer saline (PBS) to wash the solution
twice before centrifuging for 5 min at 1850 rpm.
Then a sample containing 10,000 cells from each
tube was counted in the appropriate lymphocyte
gate  using  flow  cytometry  equipped  withArch Med Sci 1, February / 2010 79
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a CELLQuest  software  program.  Finally,  the
percentage value of all the markers was determined
using the analysis program.
S St ta at ti is st ti ic ca al l   a an na al ly ys si is s   
Statistical analysis was conducted using Unistat
5.1 software. All numerical values are reported as
means ± SD. A comparison of variables between
three  groups  was  performed  using  one-way 
ANOVA. Differences between control, SP-TBC and
MDR-TB groups were determined by the Bonferroni
test. Chest X-ray, family and TB history groups were
estimated by ˇ2 test. P-values less than 0.05 were
considered significant.
Results
P Pa at ti ie en nt ts s’ ’   d de em mo og gr ra ap ph hi ic c   d de et ta ai il ls s   
As can be seen in Table I, leucocytes counts were
found to be significantly different between groups
and increases were observed in both SP-TB and
MDR-TB groups. Haemoglobin and haematocrit 
levels were found to be increased in the SP-TB
group  and  decreased  in  the  MDR-TB  group,
compared to the control group. 
Most of the MDR-TB patients had a positive
family TB history, while less distinct family histories
of tuberculosis were noted in SP-TB and control
groups, as shown in Table I.
Bilateral lesions were found to be dominant in
the MDR-TB group, while unilateral lesions were
dominant in the SP-TB group. ARB and bacillus
cultures were found in all of the patients in SP-TB
and MDR-TB groups, while none of the control
individuals had positive findings for ARB or bacillus
cultures, as can also be observed from Table I.
F Fl lo ow w   c cy yt to om me et tr ri ic c   a an na al ly ys si is s
CD4,  CD3,  Fas  (CD95),  CD3/CD25  and  CD3/ 
HLD-DR expressions were found to be significantly
decreased in  both  SP-TB  and  MDR  TB  groups
compared to the control group (Figures 1, 2). In
contrast to these findings, NKT (CD3 (+) and ʳʴ T
cell levels were found to be significantly increased,
while CD8 levels were non-significantly increased,
in both SP-TB and MDR-TB groups compared to the
control group, as shown in Figures 1 and 2.
CD45, CD19, CD16/56 (NK), HLA-DR, CD4/CD8
and CD3/CD23 levels were found to be increased
in the SP-TB group and significantly decreased in
the MDR-TB group compared to the control group
(Figures 1, 2).
Discussion
The latest WHO estimates indicate that between
250,000 and 500,000 new MDR-TB cases occur
annually, which accounts for 3-6% of all new and
C Co on nt tr ro ol l S SP P- -T TB B M MD DR R- -T TB B S Si ig g. .
( (n n = =   2 20 0) ) ( (n n = =   2 27 7) ) ( (n n = =   2 20 0) )
A Ag ge e 44.1 ±7.0 35.9 ±13.9 40.6 ±12.6 0.08a
S Se ex x    ( (M M/ /F F) ) 7/13 24/3 17/3 0.001b
S Sm mo ok ki in ng g    ( (p p/ /y ye ea ar r) ) 7.3 ±1.3 19.1 ±3.9 20.0 ±3.3 0.06a
L Le eu uk ko oc cy yt te e    ( (m mm m3 3) ) 6961.8 ±331.9  9292.5 ±460.2c 9575.0 ±525.1d 0.001a
H Ha ae em mo og gl lo ob bi in n    ( (g gr r/ /d dl l) ) 12.0 ±0.2 12.9 ±0.2 11.47 ±0.30e 0.001a
H Ha ae em ma at to oc cr ri it t    ( (% %) ) 38.3 ±0.5 39.4 ±0.8 36.0 ±0.7e 0.009b
F Fa am mi il ly y   T TB B   h hi is st to or ry y
TB negative     (n) 16 20 5
(%) 84.2 74.1 29.4
0.001
b
TB positive (n)3 7 12
(%) 15.8 25.9 70.6
C Ch he es st t   X X   r ra ay y   
Unilateral lesion (n)– 17 9
(%) – 65.4 34.6
0.001
b
Bilateral lesion (n)– 4 16
(%) – 20 80
ARB (n)– 27 20 0.0001b
(%) – 100 100
Bacillus culture positive (n)– 27 20 0.0001b
(%) – 100 100
T Ta ab bl le e   I I. .   Demographic, haematological, radiological and microbiological characteristics of control individuals, SP-TB
and MDR-TB patients
Values are represented as mean ± SD. Comparisons performed by aANOVA, p values calculated by bˇ2 test, cp < 0.05 in comparison to control
group, dp < 0.05 in comparison to SP-TB group, ep < 0.05 significance between SP-TB and MDR-TB groups, comparisons performed by 
cdeBonferroni test
SP-TB – drug-sensitive tuberculosis, MDR-TB – multidrug-resistant tuberculosis, ARB – acido-resistant bacilli80 Arch Med Sci 1, February / 2010
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previously treated TB cases. These figures indicate
an upturn in the proportion of resistant isolates and
the  authors  of  the  review  also  confirm  the
emergence  of  extensively  resistant  TB  which
includes  resistance  to  fluoroquinolones  and
aminoglycosides [16]. The emergence and spread
of drug resistance is widely recognized as posing
a public health threat of global proportions. There
is a clear correlation between late diagnosis of
disease which causes a delay in initiating effective
treatment, and unsuccessful clinical outcomes [17].
For this reason, immunological testing may have an
important role in enabling prompt diagnosis and
treatment of tuberculosis.
The  total  blood  leukocyte  counts  and  total
lymphocyte  (CD45)  levels  of  patients  varied
between all the groups; and particularly when the
MDR-TB and the SP-TB group were compared the
difference was statistically significant. Leukocyte
levels were higher in patient groups compared to
controls, while CD45 counts were lowest in the
MDR-TB  group.  This  level  represents  a small
proportion  of  the  total  leukocyte  numbers  in
patients with MDR-TB, thus indicating the presence
of lymphopenia. This low CD45 level in the MDR-
TB group draws attention to these patients’ reduced
lymphocyte response, compared to that of the 
SP-TB group. In addition, the lymphopenia observed
among  patients  with  MDR-TB  may  play  an
important role in the pathogenesis of the disease.
The lowest levels of both HLA-DR and CD3/ 
HLA-DR were seen in the MDR-TB group. These
measurements  reflect  the  low  level  of  active
lymphocytes in patients with MDR-TB. Our findings
are also consistent with a study by Rodriguez et al.,
which did not find any statistically significant
difference in the HLA-DR (+) expression index in
PPD (–), PPD (+), active tuberculosis, or treated
tuberculosis groups [8].
In patients with MDR-TB, CD4 (+) T lymphocyte
counts have been observed to be low. On the 
other hand, some studies indicate that CD3 (+) and
CD4 (+) cell counts may be higher in drug-sensitive
pulmonary TB cases [18, 19].
T lymphocytes, especially CD4 (+) T lymphocytes,
play an important role in the immune reaction
against MDR-TB. It is not clearly known whether the
effects of CD4 (+) lymphocytes to control disease
are mediated by their cytokine secretions or their
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direct effect on macrophages. Indeed there are many
inter- and intracellular processes involved; and if
some of these mechanisms can be elucidated, new
treatment strategies may be developed. 
One of the aims of our study was to find out
whether we could predict the development of 
MDR-TB  by  looking  at  the  HLA-DR  and  CD3/
HLA-DR  levels.  When  the  three  groups  were
compared, although the differences between the 
HLA-DR levels were not significant, a significant
difference was found in CD3/HLA-DR levels for
patients with MDR-TB. 
CD8 (+) T cells are essential for host defence
against intracellular bacterial pathogens such as 
M. tub. [18, 20]. Yildiz et al. found significantly lower
values of lymphocyte numbers, absolute numbers
and percentages of CD3 (+) and CD4 (+) in MDR-TB
cases when compared to SP-TB cases. Besides this,
the CD4/CD8 ratio was lower in MDR-TB cases,
when compared with SP-TB, but these results were
not statistically significant [21]. In our study, while
not  statistically  significant,  the  high  levels  of
cytotoxic CD8 (+) lymphocytes in patients with
MDR-TB may be secondary to the stimulation of
tuberculoid antigens. Alternatively an increase in
suppressor CD8 lymphocytes may be the causative
factor.  This  increase  in  CD8+  supports  the
suppression  reflected  in  the  reduction  of  the
CD4/CD8 ratio from 1.44 in the control group, and
1.36 in the SP-TB group to 1.08 in the MDR-TB
group. 
Levels of the CD19 (+) B lymphocytes responsible
for antibody production and their activation receptor
CD23  were  non-significantly  reduced  in  the 
MDR-TB group. This suggests that humoral as well
as cellular immunity is affected, and that this effect
is more profound in the MDR-TB group than the 
SP-TB group. Similarly, Cagatay et al. showed that
both humoral and cellular immune response is
suppressed in patients with MDR-TB [22].
Fas (CD95)(+) lymphocytes were found to be
significantly lower in MDR-TB patients compared
to the control group and the SP-TB patients. Fas
(CD95)(+) lymphocyte is typical for patients with
prognostically unfavourable immune abnormalities.
It is tempting to speculate that apoptosis of T cells
(possibly Th1 cells) is of great importance in the
pathogenesis of the immunodeficiency associated
with the mycobacteriosis [23]. In our study, Fas
(CD95)(+) among the three groups was highly
significant,  with  patients  with  MDR-TB
demonstrating the lowest level. This may indicate
suppression of the host immune response and may
help to shed light on MDR-TB pathogenesis.
In our study, NK (CD16/56) cells were increased
in the SP-TB group compared to healthy controls.
On  the  other  hand,  when  compared  to  both
controls and the SP-TB group, the MDR-TB group
demonstrated a profound reduction in NK levels,
indicating a dysfunctional NK response. Yildiz et al.
demonstrated that patients with MDR-TB had
significantly lower NK compared to normal TB and
controls. This reduction in NK may suggest a role
for impaired NK function in the pathogenesis of
MDR-TB [22, 23].
The level of human natural killer T cells (NKT) is
a non-invasive marker of pulmonary TB activation
and disease prognosis. The reason for a higher 
level of NKT in tuberculosis patients might be
related  to  the  high  load  of  phosphorylated
metabolites released following the phagocytosis of
bacilli by macrophages [24-26]. 
In this study, both groups of patients with TB
had significantly raised NKT levels, indicating an
active infection and a host immune protective
response against mycobacteria compared to healthy
controls. Thus, the NKT cell increase is consistent
with the presence of active infection as seen in our
patients. In addition, NKT levels may shed light on
disease progression and prognosis, and help to
distinguish  MDR-TB  from  SP-TB  disease.  The
mucosal  immune  system  showed  a similarly
significant increase in both SP-TB cases and in
patients with MDR-TB. Lockhart et al. and Lee et al.
demonstrated that in infection with Mycobacterium,
ʳʴ T cells become dominant as they are activated
by phosphorylated metabolites within phagosomes
[27,  28].  In  our  study,  there  was  a significant
increase in the level of ʳʴ T cells in the MDR-TB
group compared to the control and SP-TB groups.
To summarize these flow cytometric findings,
MDR M. tub. modifies host defence by suppressing
CD3/HLA-DR+ and Fas + T cells, but by increasing
ʳʴ-T cells and NKT cells in MDR-TB patients.
These  findings  may  shed  light  on  MDR-TB
pathogenesis, although it cannot be elucidated from
the findings whether the immune status of the
patients is reflective of their condition before or after
they succumbed to active MDR-TB infection. However,
all of the immune parameters seem to point to 
a worse prognosis in patients with MDR-TB compared
to drug-sensitive tuberculosis. It may also be possible
to  gain  valuable  information  by  measuring  the
immune parameters of individuals who had contacted
patients with a family history of MDR-TB. 
In conclusion, decreased levels of CD4, CD3/
HLA-DR+ and Fas + T cells and increased levels of
NKT and ʳʴ T cells detected by flow cytometry in
MDR-TB  cases  compared  to  drug-sensitive  TB
patients might have diagnostic value. Based on
immunological profiles it may be assumed that the
patient has developed MDR-TB, and so without the
two-month delay of culture and sensitivity testing,
empirical therapy may be started. This proposition
of course remains to be confirmed by further
research and tested in clinical practice.82 Arch Med Sci 1, February / 2010
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